Clinical experience with erythropoietin in continuous ambulatory peritoneal dialysis.
The purpose of this project was to determine a safe and effective Epogen (EPO) subcutaneous administration schedule for patients who were on continuous ambulatory peritoneal dialysis. To comply with the manufacturer's recommendation to enter a vial only once, a dosing regimen had to be established that used a standard dose of 2,000 or 4,000 units. The goal was to determine the frequency of administration that would achieve and maintain the target hematocrit. Twenty-six patients participated. The starting dose of 4,000 units was administered either two or three times per week. An average 8.3% point increase in hematocrit was seen in 8 weeks. When the target hematocrit of 33% to 35% was reached, the dose and or frequency of administration was decreased. Maintenance doses were established at 2,000 or 4,000 units weekly or biweekly. We were able to meet and maintain the target hematocrit by using 2,000 or 4,000 units per dose and adjusting the frequency.
Jensen
S R
SR
Eby
S R
SR
McMurray
S D
SD
McWilliams
M P
MP
Rice
C
C
D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D006400:Hematocrit; D006801:Humans; D007279:Injections, Subcutaneous; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000451:nursing
D004921:Erythropoietin